Cardiff Oncology公司近日公布的研究数据,为在一线治疗RAS突变转移性结直肠癌(MCR)的注册项目中选用30毫克Onvansertib剂量提供了有力支持。这一剂量选择基于临床研究中的有效性和安全性数据,有望推动该药物后续的注册审批进程。
Cardiff Oncology公司近日公布的研究数据,为在一线治疗RAS突变转移性结直肠癌(MCR)的注册项目中选用30毫克Onvansertib剂量提供了有力支持。这一剂量选择基于临床研究中的有效性和安全性数据,有望推动该药物后续的注册审批进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.